 Daniel Merrick
Concepts (309)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 41 | 2024 | 2328 | 3.070 |
Why?
| | Precancerous Conditions | 12 | 2024 | 161 | 2.530 |
Why?
| | Carcinoma, Squamous Cell | 15 | 2024 | 620 | 2.030 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 13 | 2023 | 1045 | 1.360 |
Why?
| | Adenocarcinoma | 7 | 2019 | 888 | 0.650 |
Why?
| | Bronchi | 6 | 2018 | 240 | 0.480 |
Why?
| | Chemoprevention | 4 | 2019 | 90 | 0.450 |
Why?
| | Biopsy | 8 | 2023 | 1081 | 0.420 |
Why?
| | ErbB Receptors | 6 | 2023 | 601 | 0.410 |
Why?
| | Disease Progression | 7 | 2019 | 2602 | 0.400 |
Why?
| | Biomarkers, Tumor | 8 | 2018 | 1181 | 0.390 |
Why?
| | Carmustine | 3 | 2020 | 50 | 0.390 |
Why?
| | Heat-Shock Proteins | 1 | 2012 | 131 | 0.370 |
Why?
| | Neovascularization, Pathologic | 5 | 2015 | 290 | 0.370 |
Why?
| | Bronchial Neoplasms | 2 | 2011 | 14 | 0.360 |
Why?
| | Papillomaviridae | 4 | 1996 | 113 | 0.340 |
Why?
| | Lung Diseases | 1 | 2015 | 715 | 0.310 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 639 | 0.310 |
Why?
| | Smoke | 3 | 2020 | 131 | 0.310 |
Why?
| | Keratinocytes | 4 | 1996 | 243 | 0.310 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 634 | 0.310 |
Why?
| | Lung | 10 | 2025 | 3743 | 0.310 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2024 | 325 | 0.300 |
Why?
| | Smoking | 6 | 2019 | 1460 | 0.300 |
Why?
| | Gene Dosage | 3 | 2016 | 142 | 0.290 |
Why?
| | Formaldehyde | 2 | 2025 | 57 | 0.290 |
Why?
| | Inflammation | 1 | 2018 | 2654 | 0.280 |
Why?
| | Carcinogenesis | 2 | 2020 | 209 | 0.280 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1351 | 0.270 |
Why?
| | B7-H1 Antigen | 2 | 2019 | 189 | 0.270 |
Why?
| | Epoprostenol | 2 | 2018 | 134 | 0.270 |
Why?
| | Iloprost | 4 | 2018 | 45 | 0.260 |
Why?
| | Carcinogens | 5 | 2018 | 110 | 0.260 |
Why?
| | Mice | 22 | 2025 | 16602 | 0.240 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2018 | 313 | 0.230 |
Why?
| | Humans | 51 | 2024 | 128418 | 0.230 |
Why?
| | Mutation | 6 | 2023 | 3689 | 0.230 |
Why?
| | Sputum | 4 | 2019 | 302 | 0.220 |
Why?
| | Mast Cells | 1 | 2025 | 142 | 0.220 |
Why?
| | Receptor, ErbB-2 | 1 | 2006 | 325 | 0.220 |
Why?
| | Immunohistochemistry | 5 | 2015 | 1664 | 0.220 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2003 | 16 | 0.210 |
Why?
| | Neoplasm Invasiveness | 4 | 2015 | 480 | 0.210 |
Why?
| | Chest Pain | 1 | 2003 | 89 | 0.210 |
Why?
| | Desmoglein 3 | 2 | 2022 | 16 | 0.200 |
Why?
| | Lidocaine | 1 | 2022 | 39 | 0.200 |
Why?
| | Cell Proliferation | 4 | 2018 | 2344 | 0.200 |
Why?
| | Gelatin | 1 | 2022 | 40 | 0.200 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 500 | 0.200 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2022 | 199 | 0.200 |
Why?
| | Neuropilin-1 | 1 | 2021 | 8 | 0.190 |
Why?
| | Inflammation Mediators | 1 | 2025 | 495 | 0.190 |
Why?
| | Male | 29 | 2025 | 62858 | 0.190 |
Why?
| | Ki-67 Antigen | 2 | 2015 | 107 | 0.180 |
Why?
| | Animals | 23 | 2025 | 34479 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 81 | 0.180 |
Why?
| | Female | 29 | 2022 | 68154 | 0.180 |
Why?
| | Middle Aged | 18 | 2020 | 30889 | 0.180 |
Why?
| | Cysts | 1 | 2021 | 108 | 0.170 |
Why?
| | Receptor, IGF Type 1 | 2 | 2010 | 65 | 0.170 |
Why?
| | Air Pollution | 1 | 2023 | 214 | 0.170 |
Why?
| | Aged | 13 | 2019 | 21953 | 0.170 |
Why?
| | Disease Models, Animal | 5 | 2020 | 3937 | 0.170 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 42 | 0.160 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 577 | 0.160 |
Why?
| | Carcinoma in Situ | 1 | 2019 | 45 | 0.160 |
Why?
| | Pneumonia | 1 | 2025 | 598 | 0.160 |
Why?
| | Respiratory System | 1 | 2020 | 152 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2023 | 749 | 0.160 |
Why?
| | Air Pollutants | 1 | 2023 | 312 | 0.160 |
Why?
| | Gene Expression Profiling | 2 | 2005 | 1688 | 0.160 |
Why?
| | gamma Catenin | 1 | 2018 | 13 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 1 | 2019 | 371 | 0.150 |
Why?
| | Exons | 1 | 2020 | 338 | 0.150 |
Why?
| | Metaplasia | 1 | 2018 | 54 | 0.150 |
Why?
| | Bronchial Diseases | 1 | 2018 | 38 | 0.150 |
Why?
| | Mucin 5AC | 1 | 2018 | 69 | 0.150 |
Why?
| | MicroRNAs | 2 | 2016 | 677 | 0.150 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 95 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 3 | 2023 | 872 | 0.140 |
Why?
| | Anticarcinogenic Agents | 1 | 2018 | 77 | 0.140 |
Why?
| | Tobacco Smoke Pollution | 1 | 2020 | 229 | 0.140 |
Why?
| | Aged, 80 and over | 7 | 2017 | 7033 | 0.140 |
Why?
| | RNA, Messenger | 5 | 2022 | 2675 | 0.140 |
Why?
| | Urethane | 4 | 2023 | 41 | 0.130 |
Why?
| | Cell Transformation, Viral | 2 | 1993 | 27 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 533 | 0.130 |
Why?
| | Frizzled Receptors | 1 | 2016 | 23 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2017 | 205 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 198 | 0.130 |
Why?
| | Myocardial Infarction | 1 | 2003 | 1015 | 0.130 |
Why?
| | Oncogenes | 1 | 2016 | 109 | 0.120 |
Why?
| | Porphyrins | 1 | 2015 | 21 | 0.120 |
Why?
| | Tomography, Spiral Computed | 1 | 2015 | 27 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 74 | 0.120 |
Why?
| | Topoisomerase Inhibitors | 1 | 2015 | 4 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 210 | 0.120 |
Why?
| | Smad4 Protein | 1 | 2015 | 37 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 430 | 0.120 |
Why?
| | Adult | 11 | 2018 | 35300 | 0.110 |
Why?
| | Neoplasms | 2 | 2024 | 2464 | 0.110 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 375 | 0.110 |
Why?
| | Chromosomal Instability | 1 | 2013 | 18 | 0.110 |
Why?
| | Macrophages, Alveolar | 2 | 2023 | 376 | 0.110 |
Why?
| | Mice, Transgenic | 5 | 2018 | 2071 | 0.110 |
Why?
| | Microarray Analysis | 1 | 2013 | 120 | 0.110 |
Why?
| | Stem Cells | 1 | 2018 | 578 | 0.110 |
Why?
| | Neoplasms, Basal Cell | 1 | 2013 | 3 | 0.110 |
Why?
| | Trachea | 1 | 2015 | 221 | 0.110 |
Why?
| | Endoscopy | 1 | 2015 | 266 | 0.110 |
Why?
| | Tretinoin | 1 | 1993 | 128 | 0.100 |
Why?
| | Interleukin-1 | 1 | 1996 | 961 | 0.100 |
Why?
| | Quinazolines | 2 | 2012 | 243 | 0.100 |
Why?
| | Piperidines | 2 | 2012 | 190 | 0.100 |
Why?
| | Prognosis | 5 | 2020 | 3772 | 0.100 |
Why?
| | B-Lymphocytes | 1 | 2017 | 817 | 0.100 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 52 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2013 | 157 | 0.100 |
Why?
| | Antigens, Differentiation | 1 | 1992 | 82 | 0.100 |
Why?
| | Cohort Studies | 3 | 2023 | 5388 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1559 | 0.090 |
Why?
| | Early Detection of Cancer | 1 | 2015 | 369 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1046 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 940 | 0.090 |
Why?
| | Cell Line | 4 | 2019 | 2731 | 0.090 |
Why?
| | Hyperplasia | 1 | 2011 | 170 | 0.090 |
Why?
| | Tissue Array Analysis | 3 | 2019 | 57 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1416 | 0.090 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2012 | 221 | 0.090 |
Why?
| | Epithelium | 4 | 2018 | 306 | 0.090 |
Why?
| | Pulmonary Surgical Procedures | 1 | 2010 | 8 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 945 | 0.090 |
Why?
| | Nuclear Proteins | 3 | 2006 | 657 | 0.080 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2010 | 89 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2012 | 366 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2011 | 321 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 815 | 0.080 |
Why?
| | Cell Polarity | 1 | 2010 | 140 | 0.080 |
Why?
| | Neoplasm Staging | 3 | 2020 | 1290 | 0.080 |
Why?
| | Epithelial Cells | 4 | 2018 | 1032 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2015 | 4892 | 0.080 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2008 | 65 | 0.080 |
Why?
| | Solitary Fibrous Tumor, Pleural | 1 | 2008 | 4 | 0.070 |
Why?
| | Osteoarthropathy, Secondary Hypertrophic | 1 | 2008 | 4 | 0.070 |
Why?
| | Echocardiography | 2 | 2003 | 623 | 0.070 |
Why?
| | Smokers | 2 | 2019 | 137 | 0.070 |
Why?
| | Neoplasms, Experimental | 2 | 2018 | 169 | 0.070 |
Why?
| | Fibroblast Growth Factors | 1 | 2008 | 170 | 0.070 |
Why?
| | Carcinoma, Small Cell | 1 | 2008 | 168 | 0.070 |
Why?
| | Edema | 1 | 2008 | 125 | 0.070 |
Why?
| | Monocytes | 1 | 2010 | 542 | 0.070 |
Why?
| | Radiography, Thoracic | 1 | 2008 | 164 | 0.070 |
Why?
| | Genome-Wide Association Study | 1 | 2013 | 1336 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2505 | 0.070 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2025 | 626 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5272 | 0.070 |
Why?
| | Minichromosome Maintenance Complex Component 2 | 1 | 2006 | 4 | 0.070 |
Why?
| | Placebos | 2 | 2019 | 201 | 0.060 |
Why?
| | Hydrogels | 2 | 2023 | 632 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2062 | 0.060 |
Why?
| | Treatment Outcome | 5 | 2022 | 10152 | 0.060 |
Why?
| | Biomarkers | 4 | 2023 | 3880 | 0.060 |
Why?
| | Prevalence | 2 | 2023 | 2547 | 0.060 |
Why?
| | Tumor Microenvironment | 2 | 2021 | 623 | 0.060 |
Why?
| | Transcription Factors | 1 | 1993 | 1628 | 0.060 |
Why?
| | Cell Movement | 2 | 2025 | 936 | 0.060 |
Why?
| | Mice, Inbred A | 2 | 2020 | 47 | 0.060 |
Why?
| | Hypoxia | 1 | 2012 | 1036 | 0.060 |
Why?
| | Chromosome Aberrations | 2 | 2017 | 148 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 89 | 0.060 |
Why?
| | Bronchoscopy | 2 | 2019 | 207 | 0.060 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 258 | 0.060 |
Why?
| | Prospective Studies | 4 | 2023 | 7036 | 0.060 |
Why?
| | Japan | 1 | 2003 | 96 | 0.050 |
Why?
| | Gene Knockdown Techniques | 2 | 2015 | 312 | 0.050 |
Why?
| | Keratin-5 | 1 | 2022 | 49 | 0.050 |
Why?
| | Diagnostic Errors | 1 | 2003 | 160 | 0.050 |
Why?
| | Alveolar Epithelial Cells | 1 | 2023 | 97 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2023 | 98 | 0.050 |
Why?
| | Signal Transduction | 3 | 2012 | 4826 | 0.050 |
Why?
| | Up-Regulation | 1 | 2005 | 825 | 0.050 |
Why?
| | Particle Size | 1 | 2023 | 352 | 0.050 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 385 | 0.050 |
Why?
| | Dendritic Cells | 1 | 2025 | 479 | 0.050 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 206 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2023 | 157 | 0.050 |
Why?
| | Interferon-gamma | 2 | 2018 | 759 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1228 | 0.050 |
Why?
| | PPAR gamma | 1 | 2022 | 182 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1815 | 0.050 |
Why?
| | Tubulin | 1 | 2022 | 137 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2019 | 1848 | 0.050 |
Why?
| | Incidence | 2 | 2008 | 2616 | 0.040 |
Why?
| | Particulate Matter | 1 | 2023 | 245 | 0.040 |
Why?
| | Acute Disease | 1 | 2003 | 964 | 0.040 |
Why?
| | Pain, Postoperative | 1 | 2022 | 225 | 0.040 |
Why?
| | Exercise Test | 1 | 2003 | 613 | 0.040 |
Why?
| | Oximes | 1 | 2020 | 20 | 0.040 |
Why?
| | Electrocardiography | 1 | 2003 | 604 | 0.040 |
Why?
| | Blotting, Western | 2 | 2012 | 1164 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 101 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 162 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2020 | 281 | 0.040 |
Why?
| | Imidazoles | 1 | 2020 | 226 | 0.040 |
Why?
| | Cell Line, Transformed | 2 | 1996 | 140 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2023 | 461 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 2132 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 375 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 268 | 0.040 |
Why?
| | RNA | 1 | 2005 | 880 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2021 | 330 | 0.040 |
Why?
| | Tobacco Smoking | 1 | 2018 | 25 | 0.040 |
Why?
| | Pyridones | 1 | 2020 | 159 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2018 | 62 | 0.040 |
Why?
| | Tricuspid Valve | 1 | 1998 | 27 | 0.040 |
Why?
| | Mass Screening | 2 | 2004 | 1147 | 0.040 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 571 | 0.040 |
Why?
| | Time | 1 | 2018 | 75 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 214 | 0.040 |
Why?
| | Risk Factors | 3 | 2019 | 9704 | 0.040 |
Why?
| | Ventricular Outflow Obstruction | 1 | 1998 | 40 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2018 | 128 | 0.040 |
Why?
| | Tumor Burden | 1 | 2018 | 283 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2017 | 150 | 0.030 |
Why?
| | Immunotherapy | 1 | 2021 | 587 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 150 | 0.030 |
Why?
| | Carcinogenicity Tests | 1 | 1996 | 6 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 169 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 530 | 0.030 |
Why?
| | Blotting, Northern | 1 | 1996 | 198 | 0.030 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 1996 | 35 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2016 | 4001 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 1996 | 258 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 311 | 0.030 |
Why?
| | Centrosome | 1 | 2016 | 64 | 0.030 |
Why?
| | Plasmids | 1 | 1996 | 354 | 0.030 |
Why?
| | Mitotic Index | 1 | 2015 | 26 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 408 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1263 | 0.030 |
Why?
| | Cell Differentiation | 2 | 1993 | 1900 | 0.030 |
Why?
| | Mice, Nude | 1 | 1996 | 682 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 484 | 0.030 |
Why?
| | Phenotype | 2 | 1993 | 3044 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 283 | 0.030 |
Why?
| | Uterine Cervical Neoplasms | 1 | 1996 | 232 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2013 | 46 | 0.030 |
Why?
| | Retinoid X Receptors | 1 | 1993 | 40 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 598 | 0.030 |
Why?
| | Receptors, Retinoic Acid | 1 | 1993 | 51 | 0.030 |
Why?
| | DNA Repair | 1 | 2015 | 205 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 1993 | 142 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 1098 | 0.030 |
Why?
| | Cytosol | 1 | 1993 | 214 | 0.030 |
Why?
| | Drug Resistance | 1 | 1993 | 163 | 0.030 |
Why?
| | Models, Molecular | 1 | 2018 | 1480 | 0.030 |
Why?
| | Macrophages | 1 | 2020 | 1460 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2012 | 3184 | 0.030 |
Why?
| | Methylcholanthrene | 1 | 2012 | 21 | 0.020 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2012 | 44 | 0.020 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 304 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2012 | 38 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 157 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1992 | 50 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 1992 | 57 | 0.020 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1993 | 215 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 370 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 143 | 0.020 |
Why?
| | Sleep Apnea Syndromes | 1 | 2012 | 79 | 0.020 |
Why?
| | United States | 2 | 2011 | 13830 | 0.020 |
Why?
| | Keratins | 1 | 1992 | 175 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 315 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2012 | 130 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 754 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2051 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 230 | 0.020 |
Why?
| | Carcinoma, Large Cell | 1 | 2010 | 15 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 441 | 0.020 |
Why?
| | Cell Division | 1 | 1992 | 778 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2722 | 0.020 |
Why?
| | Aneuploidy | 1 | 2010 | 92 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 814 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 402 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 212 | 0.020 |
Why?
| | Antioxidants | 1 | 2012 | 538 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2010 | 647 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 853 | 0.020 |
Why?
| | Survival Rate | 1 | 2011 | 1869 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5039 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1196 | 0.020 |
Why?
| | Skin | 1 | 1991 | 718 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 1936 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2005 | 33 | 0.020 |
Why?
| | Enzymes | 1 | 2005 | 64 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2012 | 3328 | 0.020 |
Why?
| | Species Specificity | 1 | 2005 | 568 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2005 | 478 | 0.010 |
Why?
| | Cytokines | 1 | 2012 | 1983 | 0.010 |
Why?
| | DNA Replication | 1 | 2005 | 225 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3103 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1355 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 756 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2435 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 12312 | 0.010 |
Why?
| | Risk Assessment | 1 | 2010 | 3232 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 6482 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 14454 | 0.010 |
Why?
| | Echocardiography, Transesophageal | 1 | 1998 | 91 | 0.010 |
Why?
| | Culture Techniques | 1 | 1991 | 80 | 0.010 |
Why?
| | Reference Values | 1 | 1991 | 776 | 0.000 |
Why?
|
|
Merrick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|